A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

Journal of Urology

Volumn 164, Issue 5, 2000, Pages 1768-1775

  Halling, Kevin C ^a   King, Walter ^b   Sokolova, Irina A ^b   Meyer, Reid G ^b   Burkhardt, Haleh M ^b   Halling, Amy C ^b   Cheville, John C ^b   Sebo, Thomas J ^b   Ramakumar, Sanjay ^b   Stewart, Christopher S ^b   Pankratz, Shane ^b   O'Kane, Dennis J ^b   Seelig, Steven A ^b   Lieber, Michael M ^b   Jenkins, Robert B ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic ^*

Author keywords

Bladder; Carcinoma; Cytology; Fluorescence; In situ hybridization; Urothelium

Indexed keywords

AGED; ARTICLE; CANCER DIAGNOSIS; CENTROMERE; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; UROGENITAL TRACT CANCER;

EID: 0033790972     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67104-2     Document Type: Article

References (57)

1. Cancer Statistics 1997
2. Diagnostic value of cytology of voided urine
3. Urine cytology in the detection of bladder cancer: A critical approach
4. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors
5. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer
6. Multicenter trial of the quantitative BTA-TRAK assay in the detection of bladder cancer
7. The clinical value of urinary cytology: 12 Years of experience with 615 patients
8. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group
9. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer
10. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer
11. Comparison of screening methods in the detection of bladder cancer
12. Improved detection of recurrent bladder cancer using the Bard BTA stat Test
13. The Bard BTA test: Its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer
14. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
15. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
16. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9
17. Two molecular pathways to transitional cell carcinoma of the bladder
18. Partial allelotype of carcinoma in situ of the human bladder
19. Evidence for two bladder cancer suppressor loci on human chromosome 9
20. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization
21. Deletion of the p16 and p15 genes in human bladder tumors
22. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization
23. Intratumoral heterogeneity in DNA ploidy of bladder carcinomas
24. Origins and clinical implications of aneuploidy in early bladder cancer
25. Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: Critical review of a 5-year experience
26. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer
27. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa)
28. Toward the validation of aneusomy detection by fluoresence in situ hybridization in bladder cancer: Comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations
29. Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei
30. Detection of genetic aberrations in bladder cancer using in situ hybridization
31. A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors
32. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer
33. Interphase cytogenetics as an adjunct in the cytodiagnosis of urinary bladder carcinoma. A comparative study of cytology, flow cytometry and interphase cytogenetics in bladder washes
34. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: A comparative study
35. Interphase cytogenetic diagnosis of bladder cancer on cells from urine and bladder washing
36. Longitudinal data analysis using generalized linear models
37. Urine cytology of transitional cell neoplasms
38. Reliability of urinary cytodiagnosis in urothelial neoplasms
39. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma
40. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade
41. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
42. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer
43. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
44. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma
45. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
46. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer
47. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer
48. Bladder cancer: State-of-the-art care
49. Polysomies but not Y chromosome losses have prognostic significance in pTa/pT1 urinary bladder cancer
50. Carcinoma in situ of the bladder
51. Pathology of carcinoma in situ of the urinary bladder and related lesions
52. Review of Mayo Clinic experience with carcinoma in situ
53. Bladder cancer from a perspective of 40 years
54. Diagnosis and treatment of bladder cancer